Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Early prediction of clinical response to checkpoint inhibitor therapy in human solid tumors through mathematical modeling

Joseph D. Butner, Geoffrey V. Martin, Zhihui Wang, Bruna Corradetti, Mauro Ferrari, Nestor Esnaola, Caroline Chung, David S. Hong, James Welsh, Naomi Hasegawa, Elizabeth A. Mittendorf, Steven A. Curley, Shu-Hsia Chen, Ping-Ying Pan, Steven K. Libutti, Shridar Ganesan, Richard L. Sidman, Renata Pasqualini, Wadih Arap, Eugene J. Koay, Vittorio Cristini
doi: https://doi.org/10.1101/2021.05.10.21256419
Joseph D. Butner
1Mathematics in Medicine Program, Houston Methodist Research Institute, Houston, TX 77030, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Geoffrey V. Martin
2Department of Radiation Oncology, The University of Texas M.D. Anderson Cancer Center, Houston TX 77030, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Zhihui Wang
1Mathematics in Medicine Program, Houston Methodist Research Institute, Houston, TX 77030, USA
3Department of Imaging Physics, The University of Texas M.D. Anderson Cancer Center, Houston TX 77030, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: zwang@houstonmethodist.org EKoay@mdanderson.org
Bruna Corradetti
4Department of Nanomedicine, Houston Methodist Research Institute, Houston, TX 77030, USA
5Swansea University Medical School, Singleton Park, Swansea SA28PP, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mauro Ferrari
4Department of Nanomedicine, Houston Methodist Research Institute, Houston, TX 77030, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nestor Esnaola
6Department of Surgery, Houston Methodist Cancer Center, Houston, TX 77030, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Caroline Chung
1Mathematics in Medicine Program, Houston Methodist Research Institute, Houston, TX 77030, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David S. Hong
7Department of Investigational Cancer Therapeutics, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
James Welsh
1Mathematics in Medicine Program, Houston Methodist Research Institute, Houston, TX 77030, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Naomi Hasegawa
8University of Texas Health Science Center (UTHealth), McGovern Medical School, Houston, TX 77030, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Elizabeth A. Mittendorf
9Breast Oncology Program, Dana Farber/Brigham and Women’s Cancer Center, Boston, MA 02215, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Steven A. Curley
10Michael E. DeBakey Department of Surgery, Baylor College of Medicine, Houston, TX 77030, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shu-Hsia Chen
11Immunotherapy Research Center, Houston Methodist Research Institute, Houston, TX 77030, USA
12Cancer Center, Houston Methodist Research Institute, Houston, TX 77030, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ping-Ying Pan
11Immunotherapy Research Center, Houston Methodist Research Institute, Houston, TX 77030, USA
12Cancer Center, Houston Methodist Research Institute, Houston, TX 77030, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Steven K. Libutti
13Rutgers Cancer Institute of New Jersey, New Brunswick, NJ 08901, USA
14Department of Surgery, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ 08901, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shridar Ganesan
13Rutgers Cancer Institute of New Jersey, New Brunswick, NJ 08901, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Richard L. Sidman
15Department of Neurology, Harvard Medical School, Boston, MA 02115, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Renata Pasqualini
16Rutgers Cancer Institute of New Jersey, Newark, NJ 07101, USA
17Division of Cancer Biology, Department of Radiation Oncology, Rutgers New Jersey Medical School, Newark, NJ 07103, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Wadih Arap
16Rutgers Cancer Institute of New Jersey, Newark, NJ 07101, USA
18Division of Hematology/Oncology, Department of Medicine, Rutgers New Jersey Medical School, Newark, NJ 07103, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Eugene J. Koay
2Department of Radiation Oncology, The University of Texas M.D. Anderson Cancer Center, Houston TX 77030, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: zwang@houstonmethodist.org EKoay@mdanderson.org
Vittorio Cristini
1Mathematics in Medicine Program, Houston Methodist Research Institute, Houston, TX 77030, USA
3Department of Imaging Physics, The University of Texas M.D. Anderson Cancer Center, Houston TX 77030, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

ABSTRACT

Checkpoint inhibitor therapy of cancer has led to markedly improved survival of a subset of patients in multiple solid malignant tumor types, yet the factors driving these clinical responses or lack thereof are not known. Here we present a translational mathematical model dependent on three key parameters for describing efficacy of checkpoint inhibitors in human cancer: tumor growth rate (α), tumor immune infiltration (Λ), and immunotherapy-mediated amplification of anti-tumor response (µ). The model was validated by fitting it to a compiled clinical tumor response dataset (n = 189 patients) obtained from published anti-PD-1 and anti-PD-L1 clinical trials, and then validated on an additional validation cohort (n = 64 patients) obtained from our in-house clinical trials. The derived parameters Λ and µ were both significantly different between responding versus non-responding patients. Of note, our model appropriately classified response in 81.4% of patients by using only tumor volume measurements and within two months of treatment initiation in a retrospective analysis. The model reliably predicted clinical response to the PD-1/PD-L1 class of checkpoint inhibitors across multiple solid malignant tumor types. Comparison of model parameters to immunohistochemical measurement of PD-L1 and CD8+ T cells confirmed robust relationships between model parameters and their underlying biology, demonstrating reliable methods to inform model parameters directly from biopsy samples, which are conveniently obtainable as early as the start of treatment. Together, these results suggest that the model parameters may serve as early and robust biomarkers of the efficacy of checkpoint inhibitor therapy on an individualized per-patient basis.

SIGNIFICANCE Checkpoint inhibitors have revolutionized cancer immunotherapy, but only a subset of patients with solid tumors responds clinically. The ability to predict tumor responses a priori or soon after starting therapy would allow for personalized and timely adaptive clinical applications of checkpoint inhibitor- based immunotherapy in patients. By applying a mechanistic mathematical model, we show that checkpoint inhibitor therapeutic effectiveness is accurately predictable in most patients within two months after treatment initiation. Our method may be implemented directly into clinical practice, as it relies on standard-of-care imaging and pathology. If successful in prospective studies, this model will improve selection of cancer patients for checkpoint inhibitor therapy, and perhaps for other forms of humoral- or cell-based immunotherapy.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

We gratefully acknowledge support from the Andrew Sabin Family Fellowship, Center for Radiation Oncology Research, Sheikh Ahmed Center for Pancreatic Cancer Research, GE Healthcare, Philips Healthcare, and institutional funds from the University of Texas M.D. Anderson Cancer Center. We have also received Cancer Center Support Grants from the National Cancer Institute (P30CA016672 to the University of Texas M.D. Anderson Cancer Center and P30CA072720 the Rutgers Cancer Institute of New Jersey). This research has also been supported in part by grants from the National Science Foundation Grant DMS-1930583 (Z.W., V.C.), the National Institutes of Health (NIH) 1U01CA196403 (Z.W., V.C.), 1U01CA213759 (Z.W., V.C.), 1R01CA226537 (Z.W., R.P., W.A., V.C.), 1R01CA222007 (Z.W., V.C.), U54CA210181 (Z.W., V.C.), and the University of Texas System STARS Award (V.C.). B.C. acknowledges support through the SER Cymru II Programme, funded by the European Commission through the Horizon 2020 Marie Skłodowska-Curie Actions (MSCA) COFUND scheme and the Welsh European Funding Office (WEFO) under the European Regional Development Fund (ERDF). E.K. has also received support from the Project Purple, NIH (U54CA210181, U01CA200468, and U01CA196403), and the Pancreatic Cancer Action Network (16-65-SING). M.F. was supported through NIH/NCI center grant U54CA210181, R01CA222959, DoD Breast Cancer Research Breakthrough Level IV Award W81XWH-17-1-0389, and the Ernest Cockrell Jr. Presidential Distinguished Chair at Houston Methodist Research Institute. R.P. and W.A. received serial research awards from AngelWorks, the Gillson-Longenbaugh Foundation, and the Marcus Foundation. This work was also supported in part by grants from the National Cancer Institute to S.H.C. (R01CA109322, R01CA127483, R01CA208703, and U54CA210181 CITO pilot grant) and to P.Y.P. (R01CA140243, R01CA188610, and U54 CA210181 CITO pilot grant). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

In-house patient cohort were obtained as de-identified data from a study conducted in accordance with the U.S. Common Rule and with Institutional Review Board Approval at MD Anderson (2014-1020), including waiver of informed consent.

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

The authors declare that all data supporting the results in this study are available within the paper and its Supplementary Information.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted May 10, 2021.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Early prediction of clinical response to checkpoint inhibitor therapy in human solid tumors through mathematical modeling
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Early prediction of clinical response to checkpoint inhibitor therapy in human solid tumors through mathematical modeling
Joseph D. Butner, Geoffrey V. Martin, Zhihui Wang, Bruna Corradetti, Mauro Ferrari, Nestor Esnaola, Caroline Chung, David S. Hong, James Welsh, Naomi Hasegawa, Elizabeth A. Mittendorf, Steven A. Curley, Shu-Hsia Chen, Ping-Ying Pan, Steven K. Libutti, Shridar Ganesan, Richard L. Sidman, Renata Pasqualini, Wadih Arap, Eugene J. Koay, Vittorio Cristini
medRxiv 2021.05.10.21256419; doi: https://doi.org/10.1101/2021.05.10.21256419
Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
Citation Tools
Early prediction of clinical response to checkpoint inhibitor therapy in human solid tumors through mathematical modeling
Joseph D. Butner, Geoffrey V. Martin, Zhihui Wang, Bruna Corradetti, Mauro Ferrari, Nestor Esnaola, Caroline Chung, David S. Hong, James Welsh, Naomi Hasegawa, Elizabeth A. Mittendorf, Steven A. Curley, Shu-Hsia Chen, Ping-Ying Pan, Steven K. Libutti, Shridar Ganesan, Richard L. Sidman, Renata Pasqualini, Wadih Arap, Eugene J. Koay, Vittorio Cristini
medRxiv 2021.05.10.21256419; doi: https://doi.org/10.1101/2021.05.10.21256419

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Oncology
Subject Areas
All Articles
  • Addiction Medicine (215)
  • Allergy and Immunology (495)
  • Anesthesia (106)
  • Cardiovascular Medicine (1093)
  • Dentistry and Oral Medicine (195)
  • Dermatology (141)
  • Emergency Medicine (274)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (499)
  • Epidemiology (9757)
  • Forensic Medicine (5)
  • Gastroenterology (480)
  • Genetic and Genomic Medicine (2303)
  • Geriatric Medicine (222)
  • Health Economics (462)
  • Health Informatics (1553)
  • Health Policy (732)
  • Health Systems and Quality Improvement (602)
  • Hematology (236)
  • HIV/AIDS (501)
  • Infectious Diseases (except HIV/AIDS) (11631)
  • Intensive Care and Critical Care Medicine (616)
  • Medical Education (236)
  • Medical Ethics (67)
  • Nephrology (256)
  • Neurology (2139)
  • Nursing (134)
  • Nutrition (335)
  • Obstetrics and Gynecology (426)
  • Occupational and Environmental Health (517)
  • Oncology (1172)
  • Ophthalmology (363)
  • Orthopedics (128)
  • Otolaryngology (220)
  • Pain Medicine (145)
  • Palliative Medicine (50)
  • Pathology (309)
  • Pediatrics (694)
  • Pharmacology and Therapeutics (298)
  • Primary Care Research (265)
  • Psychiatry and Clinical Psychology (2172)
  • Public and Global Health (4645)
  • Radiology and Imaging (775)
  • Rehabilitation Medicine and Physical Therapy (455)
  • Respiratory Medicine (623)
  • Rheumatology (274)
  • Sexual and Reproductive Health (225)
  • Sports Medicine (208)
  • Surgery (250)
  • Toxicology (43)
  • Transplantation (120)
  • Urology (94)